Sight Sciences (SGHT) CEO tax-related sale of 22,362 shares reported

Rhea-AI Filing Summary

Sight Sciences, Inc. President and CEO Paul Badawi, who is also a director and 10% owner, reported selling 22,362 shares of common stock on January 16, 2026 at a weighted average price of $6.62 per share. According to the filing, these shares were sold to cover his tax liability arising from the vesting of restricted stock units.

After this transaction, Badawi beneficially owns 6,025,840 shares of Sight Sciences common stock. This total includes 5,517,778 shares of common stock and 508,062 shares that will be received upon the vesting and settlement of unvested RSUs. The balance also corrects prior Form 4 reports by adding previously omitted RSUs and excluding certain stock option shares that were mistakenly included earlier.

Insider Trade Summary

Net Seller: 22,362 shares ($148,036)

Net Sell 1 txn

Insider Badawi Paul

Role President and CEO

Sold 22,362 shs ($148K)

Type	Security	Shares	Price	Value
Sale	Common Stock	22,362	$6.62	$148K

Holdings After Transaction: Common Stock — 6,025,840 shares (Direct)

Footnotes (1)

1. Reflects shares of the Issuer's common stock, par value $0.001 per share ("common stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Reflects the weighted average price at which the shares of common stock were sold. The shares were sold in multiple transactions at prices ranging from $6.44 to $6.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Includes (i) 5,517,778 shares of common stock, and (ii) 508,062 shares of common stock which shall be acquired upon the vesting and settlement of restricted stock units ("RSUs") that have not yet vested. The Reporting Person previously reported a grant of 87,800 RSUs on a Form 4 filed on February 11, 2022 (which was subsequently included under Table 1 on a Form 4 filed on January 5, 2023) and a grant of 176,600 RSUs on a Form 4 filed on March 21, 2023, which were awarded on February 9, 2022 and March 16, 2023, respectively. Of these RSU grants, 176,500 shares were inadvertently excluded from the Reporting Person's beneficially owned shares. The reported balance includes these previously excluded shares. Furthermore, the Reporting Person's Form 4 filed on February 16, 2024 inadvertently included under Column 5 of Table I 53,574 shares of common stock underlying the Reporting Person's stock options that were to vest within 60 days of the date of such filing. The reported balance on this Form 4 excludes the number of shares underlying such stock options.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Badawi Paul

(Last) (First) (Middle)

C/O SIGHT SCIENCES, INC.

4040 CAMPBELL AVE., SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/16/2026		S		22,362(1)	D	$6.62(2)	6,025,840(3)(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares of the Issuer's common stock, par value $0.001 per share ("common stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units.

2. Reflects the weighted average price at which the shares of common stock were sold. The shares were sold in multiple transactions at prices ranging from $6.44 to $6.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Includes (i) 5,517,778 shares of common stock, and (ii) 508,062 shares of common stock which shall be acquired upon the vesting and settlement of restricted stock units ("RSUs") that have not yet vested.

4. The Reporting Person previously reported a grant of 87,800 RSUs on a Form 4 filed on February 11, 2022 (which was subsequently included under Table 1 on a Form 4 filed on January 5, 2023) and a grant of 176,600 RSUs on a Form 4 filed on March 21, 2023, which were awarded on February 9, 2022 and March 16, 2023, respectively. Of these RSU grants, 176,500 shares were inadvertently excluded from the Reporting Person's beneficially owned shares. The reported balance includes these previously excluded shares. Furthermore, the Reporting Person's Form 4 filed on February 16, 2024 inadvertently included under Column 5 of Table I 53,574 shares of common stock underlying the Reporting Person's stock options that were to vest within 60 days of the date of such filing. The reported balance on this Form 4 excludes the number of shares underlying such stock options.

	/s/Jeremy Hayden, Attorney-in-Fact for Paul Badawi	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Sight Sciences (SGHT) shares did Paul Badawi sell in this Form 4?

Paul Badawi sold 22,362 shares of Sight Sciences, Inc. common stock in this reported transaction.

What was the sale price of the SGHT shares reported by Paul Badawi?

The shares were sold at a weighted average price of $6.62 per share, with individual trades ranging from $6.44 to $6.69 per share.

Why did Paul Badawi sell Sight Sciences (SGHT) shares in this transaction?

The filing states that the shares were sold to cover the Reporting Person's tax liability related to the vesting of restricted stock units.

How many Sight Sciences shares does Paul Badawi own after this transaction?

Following the transaction, Paul Badawi beneficially owns 6,025,840 shares of Sight Sciences common stock.

What portion of Paul Badawi’s SGHT holdings are unvested RSUs?

His reported beneficial ownership includes 508,062 shares that will be acquired upon the vesting and settlement of unvested restricted stock units.

Did this Form 4 for SGHT correct any prior reporting errors?

Yes. The reported balance now includes 176,500 previously omitted RSU shares and removes 53,574 stock option shares that were inadvertently counted in an earlier Form 4.